In many cases, they normalize as dosing stabilizes, side effects improve, nutrition normalizes and the body adjusts. However, if changes are persistent or distressing, they deserve to be taken seriously and managed, he added
A separate analysis done at Virginia Commonwealth University of more than 841,000 patients with stage 1, 2, or 3 breast cancer, also showed that at five and 10 years after treatment, the women who had been taking GLP-1 drugs had a stunning 60% lower death rate from any cause compared to non-GLP-1 users
Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., & Boban Blagaic, A
To date, this is the only phase 3 trial studying high-dose IVC in anti-cancer treatment